This article is more than 5 years old. Information may no longer be current.

10 takeaways from HemOnc Today Melanoma and Cutaneous Malignancies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The HemOnc Today Melanoma and Cutaneous Malignancies meeting offered the latest news, perspectives and interviews with leading clinicians on the most up-to-date research in melanoma and skin cancer.

HemOnc Today presents 10 key takeaways from the meeting that may affect your practice.

• Nivolumab (Opdivo, Bristol-Myers Squibb) and pembrolizumab (Keytruda, Merck) exhibited different toxicity profiles and appeared associated with different adverse event frequencies when used as monotherapy for melanoma. Read more.
• Michael A. Postow , MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discussed new immunotherapy targets for advanced melanoma beyond standard targets. Watch here.
• Smartphone technology can help improve the detection of melanoma, but several barriers must be overcome before it is used as more than a complementary tool. Read more.
• Immunosuppressive therapies, including anti–PD-1/PD-L1 agents, have led to durable responses among patients with Merkel cell carcinoma. However, more research is needed to fulfill unmet medical needs. Read more.
• The optimal sequence of immunotherapy and BRAF/MEK inhibition for the first-line treatment of melanoma has only been evaluated retrospectively and remains to be defined. Read more.
• Hedgehog inhibitors have demonstrated high efficacy and durability for patients with advanced basal cell carcinoma. However, these agents — which include FDA–approved agents vismodegib (Erivedge, Genentech) and sonidegib (Odomzo, Novartis) — can have long-lasting negative effects. Read more.
• Extended treatment with dabrafenib plus trametinib demonstrated consistent tolerability profiles in patients with BRAF V600–mutant melanoma. Read more.
• Preliminary and validation studies have been conducted on molecular testing methods for melanoma prognostication, but these methods have not yet been prospectively validated or incorporated into clinical treatment guidelines. Read more.
• Several blood- and tissue-based assays are in development to identify appropriate treatment options for patients with melanoma. Read more.
• Interferon and ipilimumab (Yervoy, Bristol-Myers Squibb) are options for the adjuvant treatment of many patients with melanoma, but data are lacking comparing these two agents. Read more.